What is a stock summary page? Click here for an overview.
Business Description
Laboratorio Reig Jofre SA
ISIN : ES0165359029
Compare
Compare
Traded in other countries / regions
RJF.Spain0RB1.UKFEQ1.Germany IPO Date
2006-11-07Description
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 1.25 | |||||
Interest Coverage | 7.57 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.63 | |||||
Beneish M-Score | -2.74 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.7 | |||||
3-Year EBITDA Growth Rate | 12.8 | |||||
3-Year EPS without NRI Growth Rate | 17.4 | |||||
3-Year Book Growth Rate | 2.8 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.86 | |||||
9-Day RSI | 51.69 | |||||
14-Day RSI | 51.3 | |||||
3-1 Month Momentum % | 4.67 | |||||
6-1 Month Momentum % | -3.24 | |||||
12-1 Month Momentum % | 6.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.82 | |||||
Quick Ratio | 1.05 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 139.04 | |||||
Days Sales Outstanding | 54.58 | |||||
Days Payable | 100.69 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.52 | |||||
Dividend Payout Ratio | 0.25 | |||||
3-Year Dividend Growth Rate | -3.9 | |||||
Forward Dividend Yield % | 1.52 | |||||
5-Year Yield-on-Cost % | 1.39 | |||||
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 0.24 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 58.83 | |||||
Operating Margin % | 4.29 | |||||
Net Margin % | 3.07 | |||||
FCF Margin % | 2.52 | |||||
ROE % | 6.14 | |||||
ROA % | 3.73 | |||||
ROIC % | 5.84 | |||||
3-Year ROIIC % | 138.47 | |||||
ROC (Joel Greenblatt) % | 10.44 | |||||
ROCE % | 6.9 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 20.15 | |||||
Forward PE Ratio | 14.67 | |||||
PE Ratio without NRI | 16.82 | |||||
Shiller PE Ratio | 20.52 | |||||
Price-to-Owner-Earnings | 11.23 | |||||
PEG Ratio | 1.48 | |||||
PS Ratio | 0.5 | |||||
PB Ratio | 0.99 | |||||
Price-to-Tangible-Book | 1.6 | |||||
Price-to-Free-Cash-Flow | 20 | |||||
Price-to-Operating-Cash-Flow | 6.75 | |||||
EV-to-EBIT | 14.46 | |||||
EV-to-Forward-EBIT | 15.35 | |||||
EV-to-EBITDA | 5.42 | |||||
EV-to-Forward-EBITDA | 6.42 | |||||
EV-to-Revenue | 0.61 | |||||
EV-to-Forward-Revenue | 0.71 | |||||
EV-to-FCF | 24.11 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Projected-FCF | 1.28 | |||||
Price-to-DCF (Earnings Based) | 0.98 | |||||
Price-to-DCF (FCF Based) | 1.6 | |||||
Price-to-Median-PS-Value | 0.49 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.04 | |||||
Price-to-Graham-Number | 1.1 | |||||
Price-to-Net-Current-Asset-Value | 11.48 | |||||
Earnings Yield (Greenblatt) % | 6.91 | |||||
FCF Yield % | 5 | |||||
Forward Rate of Return (Yacktman) % | 11.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Laboratorio Reig Jofre SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 419.173 | ||
EPS (TTM) (€) | 0.131 | ||
Beta | 0.96 | ||
3-Year Sharpe Ratio | -0.13 | ||
3-Year Sortino Ratio | -0.19 | ||
Volatility % | 25.93 | ||
14-Day RSI | 51.3 | ||
14-Day ATR (€) | 0.062888 | ||
20-Day SMA (€) | 2.6335 | ||
12-1 Month Momentum % | 6.75 | ||
52-Week Range (€) | 2.44 - 3.38 | ||
Shares Outstanding (Mil) | 80.06 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Laboratorio Reig Jofre SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Laboratorio Reig Jofre SA Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Laboratorio Reig Jofre SA Frequently Asked Questions
What is Laboratorio Reig Jofre SA(XMAD:RJF)'s stock price today?
The current price of XMAD:RJF is €2.64. The 52 week high of XMAD:RJF is €3.38 and 52 week low is €2.44.
When is next earnings date of Laboratorio Reig Jofre SA(XMAD:RJF)?
The next earnings date of Laboratorio Reig Jofre SA(XMAD:RJF) is .
Does Laboratorio Reig Jofre SA(XMAD:RJF) pay dividends? If so, how much?
The Dividend Yield %  of Laboratorio Reig Jofre SA(XMAD:RJF) is 1.52% (As of Today), Highest Dividend Payout Ratio of Laboratorio Reig Jofre SA(XMAD:RJF) was 0.59. The lowest was 0.25. And the median was 0.38. The  Forward Dividend Yield % of Laboratorio Reig Jofre SA(XMAD:RJF) is 1.52%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |